Related Experiment Video
Updated: Feb 6, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
EXPERIMENTAL ASSESSMENT OF THE SPECIFIC EFFICIENCY OF NEW METABOLIC DRUG RUNIKHOL ON MODELS OF NON-ALCOHOLIC FATTY
New metabolic corrector runikhol shows high efficiency in preclinical models of non-alcoholic fatty liver disease. This succinic acid-based drug positively influences metabolism, offering promise for treating metabolic syndrome with organ disorders.
Area of Science:
- Biomedical Sciences
- Pharmacology
- Metabolic Disorders
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a growing health concern linked to metabolic syndrome.
- Metabolic syndrome disrupts key metabolic pathways, leading to organ damage.
- Current treatments for NAFLD and associated metabolic dysfunction are limited.
Purpose of the Study:
- To evaluate the preclinical efficacy of a novel metabolic corrector, runikhol.
- To assess runikhol's impact on metabolic parameters in a NAFLD rat model.
- To determine the therapeutic potential of runikhol for metabolic syndrome with organ disorders.
Main Methods:
- Preclinical evaluation using a NAFLD model in laboratory rats (Wistar strain).
- Administration of the succinic acid-based drug, runikhol.
- Monitoring of key metabolic indicators and organ health.
Main Results:
- Runikhol demonstrated significant positive influence on impaired metabolic pathways.
- The drug showed high efficiency in improving metabolic parameters in the NAFLD model.
- Preclinical data suggest runikhol's beneficial effects on organ disorders associated with metabolic syndrome.
Conclusions:
- Runikhol is a promising therapeutic agent for non-alcoholic fatty liver disease.
- The succinic acid-based compound effectively corrects metabolic disturbances.
- Runikhol exhibits good prospects for treating metabolic syndrome and its related organ complications.
More Related Videos
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
Published on: April 1, 2021
06:26Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Related Concept Videos
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cell Specific Gene Expression
Drug Metabolism: Phase I Reactions